Plain-English translation of NCT07469943 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether a medication called empagliflozin can help protect your heart after you've had a heart attack. Empagliflozin is a diabetes medication, but recent research suggests it may have benefits beyond controlling blood sugar—including protecting heart function and reducing scarring. Researchers want to understand exactly how this medication helps the heart heal after a heart attack.
Heart attacks cause damage that can lead to long-term heart problems, even after successful treatment. This medication has shown promise in other heart conditions, but doctors need to understand whether it can specifically help reduce damage and improve recovery in heart attack patients.
You likely qualify if…
You likely don't qualify if…
You will take the medication daily at home for 12 months. You'll visit the hospital at baseline, then again at 3 months, 6 months, and 12 months for check-ups. At each visit, doctors will perform heart imaging tests and blood work to see how your heart is healing and how the medication is affecting your blood vessels and heart function.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
Greece
Enrollment target
~80 participants
Started
January 2026
Primary completion
August 2028
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ignatios Ikonomidis, MD;PhD
University of Athens
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.